XML 41 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
Other-Net, Expense (Income)
 9 Months Ended
Sep. 30, 2012
Nonoperating Income (Expense) [Abstract]  
Other - Net, Expense (Income) [Text Block]
Note 13: Other - Net, (Income) Expense
Other–net, (income) expense comprised the following:
 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
 
2012
 
2011
 
2012
 
2011
 
(Dollars in millions)
Income related to prepayment of Amylin's obligation (Note 4)
$
(787.8
)
 
$
—

 
$
(787.8
)
 
$
—

Interest expense
47.0

 
45.0

 
135.3

 
135.9

Interest income
(25.7
)
 
(22.2
)
 
(79.0
)
 
(55.5
)
Other
(22.0
)
 
60.6

 
5.5

 
71.8

Other-net, (income) expense
$
(788.5
)
 
$
83.4

 
$
(726.0
)
 
$
152.2



Other-net, income of $788.5 million and $726.0 million for the third quarter and the first nine months of 2012, respectively, is primarily related to the income recognized from the early payment of the exenatide revenue-sharing obligation by Amylin. See Note 4 for additional information.
Other-net, expense of $152.2 million for the first nine months of 2011 is primarily related to the partial impairment of Amyvid and liprotamase, partially offset by gains on the disposition of investment securities. In the third quarter of 2011, we recognized an expense related to the partial impairment of Amyvid (florbetapir), an acquired IPR&D asset, due to a delay in the expected product launch and lower sales projections during the early part of the product's expected life cycle, resulting in a reduction to the fair value of Amyvid. In the second quarter of 2011, we received a complete response letter from the FDA for the NDA for liprotamase, an acquired IPR&D asset, which communicated the need for us to conduct an additional clinical trial prior to a resubmission, resulting in a reduction to the fair value of liprotamase.